


Technology Development for the Fundamental Innovation and Clinical Deployment of Opto-Diagnostics (Horizon Illumination Lab Optics, Co. Ltd.)



Horizon Illumination
Lab Optics

City	Year of Establishment	Founder
Sapporo	2021	Maho AMANO, Yusuke OHBA, Ryoji ISHII, Jun-ichi ISHII

Partner VC	Latest round of Fundraising	Valuation
Green Core, Ltd.	Seed	JPY 461 million

Contact Information :
tel : 81-11-726-5050

Website : <https://www.horizonillumination.co.jp/en/>

○ Business Plan
Opto-Diagnostics is a unique technology that enables pre-treatment, single-cell-level evaluation of the efficacy of molecular targeted therapies. By substituting part of its molecular structure, the platform can be adapted to virtually all cancers treated with small-molecule targeted agents. We are developing two business applications based on this platform, i.e., (1)Drug Discovery Support and (2) Drug Sensitivity Testing for Physicians. We are working with KOLs toward obtaining regulatory approval of Opto-Diagnostics as a Software as a Medical Device (SaMD).

○ Research Outline
This project will accelerate commercialization by expanding the repertoire of Opto-Diagnostics agents and advancing development toward regulatory approval for chronic myeloid leukemia (CML). To that end, we aim to achieve the following proof-of-concept (PoC) milestones:
(1) Development of new Opto-Diagnostics agents via a bottom-up approach
(2) Development using a top-down approach (OBBA method)
(3) Development of automated image analysis software
(4) Evaluation of drug efficacy in EGFR-mutant non-small cell lung cancer
(5) Analytical and performance testing for regulatory submission for CML approval

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	STS 2025-2026FY	JPY 200 million	-